Literature DB >> 22274165

In vitro combination effects of aztreonam and aminoglycoside against multidrug-resistant Pseudomonas aeruginosa in Japan.

Hideki Araoka1, Masaru Baba, Kazuhiro Tateda, Yoshikazu Ishii, Toyoko Oguri, Katsuko Okuzumi, Tsuyoshi Oishi, Shinichiro Mori, Toshihiro Mitsuda, Kyoji Moriya, Yoshitaka Nakamori, Norio Ohmagari, Keizo Yamaguchi, Akiko Yoneyama.   

Abstract

The aim of this study was to evaluate the in vitro combination effects of aztreonam (AZT) and aminoglycosides against multidrug-resistant (MDR) Pseudomonas aeruginosa strains in Japan. We investigated 47 MDR P. aeruginosa strains collected from 8 facilities. We selected the aminoglycosides amikacin (AMK), gentamicin (GM), and arbekacin (ABK) to examine their effects when combined with AZT using the checkerboard method. Of the 47 MDR P. aeruginosa strains, 41 tested positive for metallo-β-lactamase (MBL). In all combinations, aminoglycosides decreased the minimum inhibitory concentrations of AZT in a dose-dependent manner, and there was no apparent antagonism. The combination effects were scored on a scale of 0 to 4, and statistical analysis was performed using the Wilcoxon signed-rank test. In all 47 strains, AZT + ABK (mean score, 2.02) had the highest score, followed by AZT + AMK (1.68) and AZT + GM (1.38) (ABK versus GM, P < 0.0001). In 41 MBL-positive strains, AZT + ABK (mean score, 2.05) had the highest score, followed by AZT + AMK (1.56) and AZT + GM (1.37) (ABK versus AMK, P = 0.02, and ABK versus GM, P < 0.0001). AZT + ABK was the most promising combination regimen against MDR P. aeruginosa strains; the other promising combinations were AZT + AMK and AZT + GM.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22274165

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  11 in total

1.  Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.

Authors:  Sangeetha Rajenderan; Veeraraghavan Balaji; Shalini Anandan; Rani Diana Sahni; Giannoula S Tansarli; Matthew E Falagas
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

2.  Identification and Characterization of the Sulfazecin Monobactam Biosynthetic Gene Cluster.

Authors:  Rongfeng Li; Ryan A Oliver; Craig A Townsend
Journal:  Cell Chem Biol       Date:  2016-12-22       Impact factor: 8.116

3.  Pairwise antibiotic interactions in Escherichia coli: triclosan, rifampicin and aztreonam with nine other classes of antibiotics.

Authors:  Caroline Nguyen; Alice Zhou; Ayesha Khan; Jeffrey H Miller; Pamela Yeh
Journal:  J Antibiot (Tokyo)       Date:  2016-03-09       Impact factor: 2.649

4.  In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.

Authors:  Qianru Yu; Edward F Griffin; Sophie Moreau-Marquis; Joseph D Schwartzman; Bruce A Stanton; George A O'Toole
Journal:  J Antimicrob Chemother       Date:  2012-07-26       Impact factor: 5.790

5.  New options of antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa.

Authors:  I Nakamura; T Yamaguchi; A Tsukimori; A Sato; S Fukushima; T Matsumoto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-07-29       Impact factor: 3.267

6.  Molecular analysis of the integrons of metallo-β-lactamase-producing Pseudomonas aeruginosa isolates collected by nationwide surveillance programs across Japan.

Authors:  Yoko Mano; Tomoo Saga; Yoshikazu Ishii; Ayumi Yoshizumi; Robert A Bonomo; Keizo Yamaguchi; Kazuhiro Tateda
Journal:  BMC Microbiol       Date:  2015-02-21       Impact factor: 3.605

7.  Arbekacin treatment of a patient infected with a Pseudomonas putida producing a metallo-beta-lactamase.

Authors:  Yoshiaki Iwashita; Tomoyuki Enokiya; Kei Suzuki; Kazuto Yokoyama; Akitaka Yamamoto; Ken Ishikura; Masahiro Okuda; Hiroshi Imai
Journal:  J Intensive Care       Date:  2013-10-23

Review 8.  Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens.

Authors:  Tetsuya Matsumoto
Journal:  Clin Pharmacol       Date:  2014-09-26

Review 9.  Clinical Usefulness of Arbekacin.

Authors:  Jae Hoon Lee; Chang-Seop Lee
Journal:  Infect Chemother       Date:  2016-03-31

Review 10.  Pseudomonas aeruginosa ventilator-associated pneumonia management.

Authors:  Sergio Ramírez-Estrada; Bárbara Borgatta; Jordi Rello
Journal:  Infect Drug Resist       Date:  2016-01-20       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.